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Abstract 
Background: Several interventions have been put in place to promote access to quality malaria case management 
services in Uganda’s private sector, where most people seek treatment. This paper describes evidence using a mixed-
method approach to examine the role, readiness and performance of private providers at a national level in Uganda. 
These data will be useful to inform strategies and policies for improving malaria case management in the private sector.
Methods: The ACTwatch national anti-malarial outlet survey was conducted concurrently with a fever case manage-
ment study. The ACTwatch nationally representative anti-malarial outlet survey was conducted in Uganda between 
May 18th 2015 and July 2nd 2015. A representative sample of sub-counties was selected in 14 urban and 13 rural 
clusters with probability proportional to size and a census approach was used to identify outlets. Outlets eligible for 
the survey met at least one of three criteria: (1) one or more anti-malarials were in stock on the day of the survey; 
(2) one or more anti-malarials were in stock in the 3 months preceding the survey; and/or (3) malaria blood testing 
(microscopy or RDT) was available. The fever case management study included observations of provider-patient 
interactions and patient exit interviews. Data were collected between May 20th and August 3rd, 2015. The fever case 
management study was implemented in the private sector. Potential outlets were identified during the main outlet 
survey and included in this sub-sample if they had both  artemisinin-based combination therapy (ACT) [artemether–
lumefantrine (AL)], in stock on the day of survey as well as diagnostic testing available.
Results: A total of 9438 outlets were screened for eligibility in the ACTwatch outlet survey and 4328 outlets were 
found to be stocking anti-malarials and were interviewed. A total of 9330 patients were screened for the fever case 
management study and 1273 had a complete patient observation and exit interview. Results from the outlet survey 
illustrate that the majority of anti-malarials were distributed through the private sector (54.3%), with 31.4% of all 
anti-malarials distributed through drug stores and 14.4% through private for-profit health facilities. Availability of dif-
ferent anti-malarials and diagnostic testing in the private sector was: ACT (80.7%), quality-assured (QA) ACT (72.0%), 
sulfadoxine–pyrimethamine (SP) (47.1%), quinine (73.2%) and any malaria blood testing (32.9%). Adult QAACT ($1.62) 
was three times more expensive than SP ($0.48). The results from the fever case management study found 44.4% of 
respondents received a malaria test, and among those who tested positive for malaria, 60.0% received an ACT, 48.5% 
received QAACT; 14.4% a non-artemisinin therapy; 14.9% artemether injection, and 42.5% received an antibiotic.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Malaria Journal
*Correspondence:  hkaula@pace.org.ugmlittrell@psi.org 
1 Population Services International, 1120 19th St NW Suite 600, 
Washington, DC 20036, USA; 2 Programme for Accessible Communication 
and Education (PACE) Uganda, Plot # 2, Ibis Vale, Kololo-off Prince Charles 
Drive, Kampala, Uganda
Full list of author information is available at the end of the article
Page 3 of 15ACTwatch Group et al. Malar J  (2017) 16:219 
Background
The private sector is an important provider of health 
services in Uganda, with up to 80% of patients seeking 
treatment from this sector [1, 2]. Private health facilities 
in Uganda have included private for-profit hospitals and 
clinics, pharmacies and drug stores—the latter which can 
be licensed and unlicensed private sector outlets [3]. In 
particular, drug stores, which constitute a large propor-
tion of Uganda’s private sector have been found to be 
one of the first points of care with an estimated 50% of 
all anti-malarials distributed through these outlets [2, 4].
Since 2004, the Ugandan anti-malarial treatment policy 
has stipulated the use of artemisinin-based combina-
tion therapy (ACT) for uncomplicated malaria. Prior to 
2010, these treatment guidelines advocated for presump-
tive treatment of all suspected malaria cases, and it was 
stipulated that even confirmed negative cases were to 
be administered ACT [5]. The goal of this blanket policy 
was to reduce the risk of severe illness or death as a result 
of malaria [6]. However, since 2010 the guidelines have 
been updated to specify that prior to treatment, all cases 
of suspected malaria should receive a malaria blood test, 
and only patients testing positive for malaria should be 
administered an ACT [7].
These policy changes have been complemented by 
several private sector initiatives to ensure patients are 
tested and treated according the national malaria treat-
ment guidelines. Uganda’s current policy stipulates that 
licensed private sector outlets are authorized to sell over-
the-counter medicines including anti-malarials (and 
ACT as of 2008) but not antibiotics or injections [8]. 
Diagnostic testing with rapid diagnostic tests (RDTs) is 
only permitted in approved pilot areas of the country.
In 2010, Uganda participated in the Affordable Medi-
cines Facility-malaria (AMFm) with the aim of increasing 
uptake of quality-assured ACT (QAACT) and decreas-
ing use of artemisinin monotherapies. The programme 
was designed as a ‘factory-gate’ subsidy, reducing the 
cost of ACT to public and private sector first-line buy-
ers by roughly 95% [9]. Following the AMFm pilot phase 
from 2010 to 2011, the programme of subsidies and 
price negotiations continued as part of Uganda’s malaria 
funding application to the Global Fund, and was called 
the Private Sector Co-payment Mechanism (CPM) for 
QAACT. Several supporting interventions in Uganda 
planned for implementation for the subsidy programme 
included behaviour change communications (BCC), the 
training of private sector providers, and the introduc-
tion of recommended retail prices for QAACT; however, 
there were challenges which prevented the BCC activities 
from being implemented [10]. All subsidized QAACT 
packaging carried a green leaf logo as an indication of 
quality and affordable anti-malarial treatment. The Inde-
pendent Evaluation of the AMFm concluded that overall 
there was a significant increase in availability of QAACT 
in the private sector following AMFm implementation, 
from 11.3% in 2010 to 65.5% in 2011 [11].
Aside from the CPM, more recent examples of strat-
egies to improve malaria case management services 
include the introduction of malaria diagnostics into 
licensed private outlets, typically drug shops [12–14]. 
These pilot interventions have included the provision of 
subsidized RDTs and have been implemented with sup-
portive interventions, including training and supervision 
of providers. Several studies have concluded that RDTs 
can be stocked and used safely to treat malaria outside 
formal health facilities in Uganda [15, 16] and that their 
use can lead to reduced prescription of anti-malarial 
drugs among RDT negative patients [12, 13, 17]. Given 
these positive findings, the policy on diagnostic testing in 
the private sector is under review by the government.
The various private sector investments discussed 
above have played an important role in improving pri-
vate sector malaria case management readiness and 
performance in Uganda. Contemporary malaria case 
management market data on anti-malarials and malaria 
diagnostics will provide an important benchmark of this 
success. Since 2008, the ACTwatch project has been 
implemented in Uganda to monitor anti-malarial and 
diagnostic markets. To date, five national outlet surveys 
have been implemented across the country. This paper 
describes evidence from Uganda’s last survey round 
implemented in 2015 and examines the role, readiness 
and performance of private providers at a national level 
in Uganda. It is complemented with a fever case man-
agement survey to explore the performance of private 
sector and adherence to national guidelines by pri-
vate providers. These data will be useful to inform and 
improve strategies and policies for malaria case manage-
ment in Uganda’s private sector.
Conclusion: The private sector plays an important role in malaria case management in Uganda. While several private 
sector initiatives have improved availability of QAACT, there are gaps in malaria diagnosis and distribution of non-arte-
misinin monotherapies persists. Further private sector strategies, including those focusing on drug stores, are needed 
to increase coverage of parasitological testing and removal of non-artemisinin therapies from the marketplace.
Keywords: Private sector, Case management, Anti-malarial, ACT, Diagnostics, RDT
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Methods
The ACTwatch national anti-malarial outlet survey was 
conducted concurrently with the fever case management 
study, but they differed in their design and sampling 
approaches.
Outlet survey
The ACTwatch nationally representative anti-malarial 
outlet survey was conducted in Uganda between May 
18th 2015 and July 2nd 2015. A representative sample of 
27 sub-counties was selected in urban (14) and rural (13) 
domains with probability proportional to size. Within 
selected clusters, a census of all outlets with the potential 
to sell or distribute anti-malarials and/or provide malaria 
blood testing was completed. In Uganda, these outlet 
types included public health facilities, community health 
workers (CHW), private not-for-profit health facilities, 
private for-profit health facilities, pharmacies, and drug 
stores. Additional sub-counties were selected for over-
sampling of public health facilities and pharmacies. This 
booster sampling strategy was used to obtain a sufficient 
sample size for indicator estimates within these impor-
tant outlet types.
The outlet survey was powered to detect a minimum 
of a 20% point change in availability of QAACT among 
anti-malarial stocking outlets between each round and 
within each domain at the 5% significance level with 80% 
power. The number of survey clusters was calculated for 
each research domain based on the required number of 
anti-malarial stocking outlets and assumptions about 
the number of anti-malarial stocking outlets per cluster. 
Sample size requirements for the 2015 survey were calcu-
lated using information from the previous survey round 
including anti-malarial and QAACT availability, outlet 
density per cluster, and design effect.
To implement the census, interviewers moved system-
atically through each of the selected clusters, looking 
for the aforementioned outlets. Where available, lists of 
registered licensed outlets were used to help identify any 
outlets. Snowball sampling was also used by interviewers 
to make sure all potential outlets were identified during 
the census process. Maps, illustrating local boundaries, 
were also used to identify the administrative boundaries 
of each cluster.
Outlets were screened to determine eligibility. Outlets 
eligible for the survey met at least one of three criteria: 
(1) one or more anti-malarials were in stock on the day of 
the survey; (2) one or more anti-malarials were in stock 
in the 3 months preceding the survey; and/or (3) malaria 
blood testing (microscopy or RDT) was available.
Among outlets that met the criteria, the main ques-
tionnaire with a malaria and RDT audit sheet was 
administered to consenting providers. Providers were 
asked to show the interviewer all anti-malarials cur-
rently available. A product audit sheet captured informa-
tion for each unique anti-malarial product in the outlet, 
including formulation, brand name, active ingredients 
and strengths, package size, manufacturer and coun-
try of manufacture. Providers were asked to report the 
retail and wholesale price for each medicine as well as the 
amount distributed to individual consumers in the last 
week.
Quality control measures implemented during data 
collection included questionnaire review by supervisors 
and interview verification visits conducted by quality 
controllers among 10 and 20% of all outlets.
Fever case management study
The fever case management study employed a cross-sec-
tional quantitative design, including observations of pro-
vider-patient interactions and patient exit interviews. Data 
were collected between May 20th and August 3rd, 2015.
The fever case management study was implemented in 
the private sector, among private for-profit health facili-
ties, pharmacies and drug stores. Potential outlets were 
identified during the main outlet survey and included 
in this sub-sample if they had both the first-line treat-
ment ACT [artemether–lumefantrine (AL)], in stock on 
the day of survey as well as diagnostic testing available. 
Observation and exit interviews were conducted within 
a few days of completion for the the main outlet survey.
The target population for the fever case management 
study included providers and patients, or their car-
egivers, seeking fever treatment. The inclusion criteria 
were: patients (or their caregivers) with fever or history 
of fever, seeking care at the outlet for this fever for the 
first time; minimum 18 years of age (or 2 months of age 
providing the caregiver was at least 18 years of age); not 
currently pregnant; and not experiencing symptoms of 
severe illness.
Among eligible outlets with consenting providers, 
patients or their caregivers seeking treatment for fever 
were sampled for inclusion in the study. All patients 
meeting eligibility criteria as outlined above were invited 
to participate in the study. A quota sampling approach 
was used, with the aim of achieving two interviews per 
outlet: one from a caregiver on behalf of a child under 
the age of five and one from an adult/or the caregiver of 
a patient over the age of five. Following informed con-
sent procedures, a structured observation checklist was 
completed by an interviewer observing the interactions 
that the patient had with providers as she/he was pro-
vided with services at the outlet. The observation was 
concerned primarily with provider behaviors, including 
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the provider assessment of the patient, the administra-
tion of RDT and counseling for treatment with ACT. A 
brief exit interview was completed with the patient when 
he or she left the outlet. The exit interview was con-
cerned with capturing information about all medicines 
prescribed/obtained. The exit interview also assessed the 
patient understanding of the test result(s) and medica-
tion regimens prescribed. Once the quota of two inter-
views per outlet was achieved, the interviewers moved 
on to the next eligible outlet. A maximum of 1 day was 
spent at the outlet by interviewers, and if the patient 
quota was not met, the interviewers moved to the next 
outlet.
Training
Interviewers, supervisors, and quality controllers 
received training that included an orientation to the 
study designs and questionnaires, classroom training on 
completing observation and exit interviews, and a prac-
tice field exercise. Additional training was provided for 
supervisors and quality-controllers focused on field mon-
itoring, verification visits, and census procedures.
Protection of human subjects
Both the main outlet survey and the fever case man-
agement study were submitted for ethical review. The 
application was reviewed and approved by the Makerere 
University College of Health Sciences School of Medicine 
Research Ethics Committee (REC REF No. 2008-057). 
The PSI Research Ethics Board ceded review to the eth-
ics committee in Uganda. Provider interviews, patient 
consultation observation, and patient exit interviews 
were completed only after administration of a standard 
informed consent form and patient/provider consent to 
participate in the study. Patients and providers had the 
option to end the interview at any point during the study. 
Standard measures were employed to maintain confiden-
tiality and anonymity.
Data entry
Different approaches were used for the main outlet sur-
vey and the fever case management study. A structured 
questionnaire programmed into mobile phones using 
DroidDB software was used to complete an audit of all 
anti-malarials and RDTs as well as a provider interview 
for the main outlet survey. Paper questionnaires were 
used to collect data for the fever case management study. 
A Microsoft Access (©Microsoft, Redmond, WA) data-
base was developed and used to conduct double data 
entry from fever case management questionnaires. Veri-
fication records from data entry and supervisor monitor-
ing sheets were reviewed and used to confirm complete 
data entry.
Analysis
Stata 13.1 (©StataCorp, College Station, TX) was used to 
clean and analyse data from the outlet survey and fever 
case management study. Sampling weights were applied 
to account for variations in probability of selection and 
standard error estimation accounted for clustering at 
the sub-district level for the outlet survey. All point esti-
mates were weighted using survey settings and all stand-
ard errors calculated taking account of the clustered and 
stratified sampling strategy with the relevant suite of sur-
vey commands.
For the outlet survey, standard indicators were con-
structed according to definitions applied across the 
ACTwatch project and have been described in detail 
elsewhere [18, 19]. Briefly, anti-malarials identified dur-
ing the outlet drug audit were classified according to 
information on drug formulation, active ingredients 
and strengths as non-artemisinin therapies, artemisinin 
monotherapies and ACT. Non-artemisinin therapies 
were classified as sulfadoxine–pyrimethamine (SP), or 
other non-artemisinin therapies. Artemisinin mono-
therapies were further classified as oral and non-oral, the 
latter including medicines recommended for the first-
line treatment of severe malaria. ACT were classified 
as QAACT or non QAACT. QAACT were either ACT 
products granted World Health Organization (WHO) 
prequalification, those granted regulatory approval by 
the European Medicines Agency (EMA) or those in com-
pliance with the Global Fund Quality Assurance Policy. 
Classification was completed by matching product audit 
information (formulation, active ingredients, strengths, 
manufacturer, country of manufacturer and package size) 
to the most recent lists of approved medicines available 
from the WHO, EMA and Global Fund.
Anti-malarial availability and malaria diagnostic avail-
ability is presented out of all screened outlets in the pri-
vate sector and by outlet type.
To calculate market share, anti-malarial sales were 
standardized to allow meaningful comparisons between 
anti-malarials with different treatment courses and dif-
ferent formulations. The adult equivalent treatment dose 
(AETD) was defined as the amount of active ingredient 
required to treat an adult weighing 60  kg according to 
WHO treatment guidelines [7]. Provider reports on the 
amount of the drug sold or distributed during the week 
preceding the survey were used to calculate volumes in 
AETDs according to type of anti-malarial. Measures of 
volume include all dosage forms to provide a complete 
assessment of anti-malarial market share. Market share is 
presented within the private sector and within each pri-
vate sector outlet type.
Price data presented were collected in Ugandan shil-
ling and converted to United States dollars using local 
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exchange rates for the period of data collection.  The 
price of QAACT was presented as the price of pre-
packaged therapy for a 60 kg adult (i.e. AL 20/120, pack-
age size of 24 tablets), and the price of pre-packaged 
therapy for a 10 kg child (i.e. AL 20/120 package size of 
6 tablets). Median private sector price per AETD was 
also calculated for QAACT and for the most popular 
non-artemisinin therapy in the most recent round, SP. 
The interquartile range (IQR) is presented as a measure 
of dispersion. While all QAACT are by definition tab-
let formulations, SP may be available in other formula-
tions including syrups and injections. Price measures for 
QAACT, SP, adult QA AL and child QA AL included tab-
let anti-malarials only, given differences in unit costs for 
tablet and non-tablet formulations. Price was also calcu-
lated for an ampule of quinine and artemether injection, 
and presented separately.
The private sector price of a malaria test using micros-
copy or RDT was assessed through provider reports of 
consumer prices.  Providers were asked to report the 
total cost of testing to a customer including any consul-
tation or service fees. Median private sector price for 
microscopy or RDTs was calculated and reported with 
the IQR as a measure of dispersion.
The fever case management indicators include 
respondents that completed both the observation 
and exit interview components. Indicators include a 
description of the sample, including whether or not the 
febrile patient was present at the consultation and if the 
respondent had sought treatment elsewhere. Point esti-
mates were also calculated to present data on whether 
or not the respondent received a test, the type of test 
received, and the result of the test (tested positive, tested 
negative, not tested). The types of medicines received 
were classified according to anti-malarials as well as 
antipyretics, and antibiotics.
Results
Outlet survey
A total of 9438 outlets were screened for availability of 
anti-malarials and/or malaria blood testing services. 
Of screened outlets, 4598 were stocking anti-malarials 
or testing on the day of the survey or within the past 
3  months, and 4724 were subsequently interviewed 
(Additional file 1: Table S1).
Anti‑malarial market share
Figure  1 illustrates the market share of anti-malarials 
distributed according to different outlet types and by 
sector. The majority of the anti-malarials were distrib-
uted through the private sector (54.3%), with third of all 
anti-malarials distributed through drug stores (31.4%), 
followed by private for-profit health facilities (14.1%) 
and pharmacies (8.8%). In comparison, 45.7% of the anti-
malarial market share was distributed through the pub-
lic sector, with most anti-malarials being administered 
through public health facilities (40.0%).
Anti‑malarial market share within the private sector
Figure 2 illustrates the market share of different classes 
of anti-malarials distributed within the private outlets 
and for the total private sector. Across the private sec-
tor, ACT was the most commonly distributed type of 
anti-malarial (66.1%) and most commonly QAACT 
(47.5%). Most of the QAACT market share was found 
in drug stores (52.9%), followed by private for-profit 
health facilities (41.5%) and pharmacies (38.0%). 
Across the private sector, SP comprised 21.3% of the 
anti-malarial market share. No oral artemisinin mono-
therapy products were found. Non-oral artemisinin 
therapy made up 1.7% of the overall private market 
share.
Public Health Facility
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Private Not For Profit Facility
Private For Profit Facility
Pharmacy
Drug Store
Fig. 1 Anti-malarial market share
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Availability of anti‑malarials and testing
Table  1 illustrates availability of anti-malarials and 
malaria diagnostic tests among all screened private sector 
outlets. Among all screened outlets, 93.4% had an anti-
malarial in stock on the day of survey. ACT was stocked 
in 80.7% of the private sector; availability of QAACT was 
72.0%. Oral quinine was the most commonly available 
non-artemisinin therapy (73.2%), followed by SP (47.1%).
Malaria blood testing was available in 32.9% of pri-
vate sector outlets, and highest among private for-
profit facilities (70.6%) followed by pharmacies (51.4%) 
and drug stores (20.9%). Availability of parasitological 
testing was mainly attributed to RDT, with the excep-
tion of private for-profit facilities where both micros-
copy (42.0%) and RDT (47.4%) were available at similar 
levels.
Table 1 Availability of malaria testing and anti-malarials, among all screened private sector outlets
a Other non-artemisinin therapy included: amodiaquine, atovaquone-proguanil, chloroquine, hydroxychloroquine sulphate, mefloquine, primaquine
Availability among all outlets Private for‑profit health 
facility
Pharmacy Drug store Total private sector
N = 1023
% (CI)
N = 493
% (CI)
N = 1967
% (CI)
N = 3483
% (CI)
Anti-malarials
Any anti-malarial 93.1 (90.4, 95.1) 98.3 (96.4, 99.2) 93.4 (91.3, 95.0) 93.4 (91.8, 94.7)
Any ACT 80.3 (74.2, 85.3) 97.9 (96.1, 98.9) 80.4 (76.9, 83.5) 80.7 (77.3, 83.6)
Any QAACT 69.5 (63.2, 75.1) 94.8 (91.6, 96.8) 72.3 (68.2, 76.0) 72.0 (68.2, 75.4)
SP 48.5 (42.1, 54.8) 82.5 (76.3, 87.3) 45.9 (40.3, 51.7) 47.1 (42.1, 52.1)
Oral quinine 65.9 (60.7, 70.8) 94.1 (89.1, 96.8) 75.0 (70.8, 78.9) 73.2 (69.5, 76.6)
Other non-artemisinin  therapya 9.1 (6.2, 13.2) 53.5 (43.1, 63.6) 10.5 (8.4, 13.1) 10.8 (9.1, 12.8)
Injectable quinine 67.1 (60.2, 73.4) 79.5 (70.1, 86.5) 20.0 (16.5, 24.0) 31.9 (28.5, 35.6)
Non oral artemisinin monotherapy 47.7 (42.2, 53.3) 84.0 (77.0, 89.2) 10.9 (8.2, 14.4) 20.6 (17.5, 24.1)
Malaria diagnostic testing
Any diagnostic 70.6 (63.6, 76.7) 51.4 (44.1, 58.6) 20.9 (17.8, 24.4) 32.9 (29.4, 36.5)
RDT 47.4 (41.4, 53.4) 51.4 (44.1, 58.6) 20.1 (17.1, 23.4) 26.8 (23.9, 30.0)
Microscopy 42.0 (35.1, 49.1) 0.6 (0.2, 1.4) 1.2 (0.6, 2.3) 10.6 (8.5, 13.2)
Readiness for malaria case management (ACT and malaria testing)
Quality assured ACT and testing 52.5 (46.2, 58.6) 49.0 (41.9, 56.1) 16.1 (13.6, 19.0) 25.1 (22.2, 28.4)
Table 2 Median private sector price of malaria testing and anti-malarials
Private for‑profit facility Pharmacy Drug store Private sector total
Median  [IQR](N of products) Median  [IQR](N of products) Median  [IQR](N of products) Median  [IQR](N of products)
Median price of a package of
 Adult QA AL $1.62 [1.29–2.26] (664) $1.29 [0.97–1.62] (670) $1.62 [1.29–1.62] (1269) $1.62 [1.29–1.94] (2603)
 Pediatric QA AL $0.65 [0.32–0.97] (84) $0.48 [0.32–0.97] (134) $0.32 [0.29–0.48] (173) $0.39 [0.32–0.58] (391)
Median price of tablet AETD
 QAACT $1.94 [1.29–3.23] (1365) $1.28 [$0.97–$1.94] (1467) $1.55 [$0.97–$1.94] (2446) $1.62 [$1.13–$1.94] (4811)
 SP $0.65 [0.48–0.81] (605) $0.48 [0.48–0.65] (587) $0.48 [0.48–0.65] (1122) $0.48 [0.48–0.65] (2314)
Median price of an ampoule
 Quinine injection $0.81 [0.48–1.13] (691) $0.48 [0.32–0.81] (453) $0.81 [0.32–0.65] (307) $0.97 [0.48–0.97] (1451)
 Artemether injection $0.97 [0.81–1.62] (455) $0.54 [0.39–0.65] (393) $0.81 [0.48–0.97] (162) $0.97 [0.65–1.29] (1010)
Median price of a microscopy
 Adult $0.97 [0.65–0.97] (409) $1.62 [0.97–1.62] (8) $0.65 [0.48–0.97] (19) $0.97 [0.65–0.97] (436)
 Child under age five $0.97 [0.65–0.97] (410) $1.62 [0.97–1.62] (8) $0.65 [0.48–0.97] (18) $0.81 [0.65–0.97] (436)
Median price of RDT
 Adult $0.97 [0.65–0.97] (513) $0.97 [0.32–0.97] (44) $0.65 [0.65–0.97] (390) $0.81 [0.65–0.97] (947)
 Child under five $0.97 [0.65–0.97] (514) $0.97 [0.32–0.97] (44) $0.65 [0.65–0.97] (391) $0.81 [0.65–0.97] (949)
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ACT and malaria testing was available 25.1% of all pri-
vate sector outlets. This was highest among private for-
profit facilities (52.5%), followed by pharmacies (49.0%) 
and drug stores (16.1%).
Price of malaria testing and anti‑malarials
In the private sector, the median retail price of a pack-
age of adult QA AL was four times more expensive than 
pediatric QA AL ($1.62 and $0.39 respectively). An 
AETD of QAACT was also three times more expen-
sive than an AETD of SP ($1.62 and $0.48 respectively) 
(Table 2). Anti-malarials were typically less expensive in 
pharmacies and drug stores as compared to private for-
profit facilities.
The median retail price for an adult microscopy and 
RDT was $0.97 and $0.81, respectively. The retail price of 
an adult and child RDT was $0.81. Malaria diagnosis was 
least expensive in drug stores compared to other private 
sector outlet types and the price did not differ by type of 
test ($0.65).
Fever case management results
A total of 1266 outlets were identified during the national 
outlet survey that met the fever case management survey 
eligibility criteria. Of these eligible outlets, 1146 outlets 
were visited for the fever case management study. There 
were 1089 outlets that participated in patient screening 
and 259 outlets that did not have any eligible patients. Of 
Table 3 Description of fever patients, by outlet type
Private for‑profit 
health facility
Pharmacy Drug store All private sector 
outlets
N = 630 N = 219 N = 424 N = 1273
Respondent is the patient and present at the outlet/con-
sultation
85.4 (79.5–89.9) 49.4 (36.5–62.3) 65.3 (58.9–71.2) 74.2 (69.5–78.4)
Prior to the current visit, the percent of all respondents that:
Sought treatment from another source 20.8 (16.7–25.7) 37.6 (28.8–47.2) 24.4 (19.3–30.4) 23.1 (19.7–27.0)
Sought treatment from a public sector source 5.9 (3.6–9.4) 18.0 (12.7–25.0) 12.8 (8.9–17.9) 9.7 (7.4–12.6)
Sought treatment from a private sector source 14.9 (11.3–19.3) 19.9 (9.8–36.3) 15.6 (10.3–22.8) 13.8 (10.7–17.7)
Received a malaria blood test from a previous treatment 
source
6.5 (4.3–9.8) 25.5 (17.3–35.9) 8.5 (5.1–14.0) 8.6 (7.0–10.5)
Received any medicine from a previous treatment source 19.6 (15.6–24.4) 16.7 (10.1–26.4) 22.8 (16.8–30.0) 20.5 (16.8–24.6)
Received an anti-malarial from a previous treatment source 12.4 (9.0–16.8) 7.1 (3.3–14.6) 13.0 (9.8–17.2) 12.5 (9.9–15.8)
Received a RDT
Received a RDT and malaria microscopy
Received malaria microscopy
Present, did not receive a malaria test
Not present (did not receive a malaria test)
All Private Sector Outlet Types
N = 1,273N=219
Pharmacies
N=424
Drug Stores
N=630
Private for-Profit Health Facilities
Fig. 3 Percentage of respondents who received a malaria blood test, across outlet type
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a total of 830 outlets with complete patient observation 
and exit interviews, 423 were private for-profit health 
facilities, 147 were pharmacies and 260 were drug stores.
A total of 9330 patients were screened during the 
fever case management study. Of these patients, 1273 
had complete patient observations and exit interviews. 
The age of the patient observations and exit interviews 
ranged from 0 years to over 50 years: 545 patients were 
between 0 and 4 years; 170 patients were between 5 and 
14 years; 503 patients were between 15 and 49 years and 
49 patients were over 50 years of age (age data were miss-
ing for 6 respondents).
Fever case management study sample description
Table  3 provides a description of fever patients who 
were eligible for the fever case management study and 
had completed both observation and exit interviews. 
The results show that across the private sector, 74.2% of 
respondents were patients seeking treatment at outlets 
as compared to 25.8% of respondents that were seeking 
treatment on behalf of the patient. 23.1% of respondents 
had sought treatment elsewhere prior to being inter-
viewed at the facility and this first source of treatment 
was most commonly from other private facilities (13.8%) 
rather than the public sector (9.7%). Among all respond-
ents, 8.6% reported receiving a malaria test, 20.5% 
received a medicine, and 12.5% an anti-malarial at a pre-
vious treatment source.
Malaria blood testing
Figure  3 shows the relative distribution of respondents 
at the outlet according to whether or not they received a 
malaria diagnostic test, for the private sector and by out-
let type. Almost half of all respondents received a malaria 
test (44.4%), and the most common type of test received 
was RDT (28.8%). Malaria testing was most common 
among private for-profit facilities (63.0%), followed by 
drug stores (29.0%). In 48.5% of pharmacies and 35.6% 
of drug stores, respondents were patients present at the 
outlet and did not receive a test.
Fever treatment by malaria test results
Table  4 illustrates the treatment outcome by malaria 
test result. Among respondents who tested positive for 
malaria, 83.0% received an anti-malarial, 60.0% received 
ACT and 48.5% received QAACT. QAACT was most 
commonly administered to confirmed positive patients 
at drug stores (68.4%) (Additional file 2: Table S2). 14.4% 
of confirmed positive patients received non-artemisinin 
therapy, mainly quinine injections, tablets or syrups, SP 
tablets or chloroquine tablets, or an artemisinin mono-
therapy, which primarily consisted of artemether injec-
tions (14.9%). Furthermore, 78.7% of all patients with 
a positive malaria test received an antipyretic (78.7%), 
while 42.5% received an antibiotic.
Among patients testing negative for malaria, 14.3% 
were administered an anti-malarial, 10.2% received an 
ACT, and 3.6% a non-artemisinin therapy. Over half 
received an antibiotic (54.7%) and 61.2% received an anti-
pyretic (Table 4).
Among patients who were not tested for malaria, 50.8% 
were treated with an anti-malarial, 42.7% were treated 
with ACT and 33.9% QAACT, and 8.4% were given a 
non-artemisinin therapy. 24.1% were treated with an 
antibiotic and 64.9% were given an antipyretic (Table 4).
Discussion
The private sector in Uganda was responsible for most 
of the anti-malarial distribution, with more than half of 
anti-malarials administered through this sector in 2015. 
Table 4 Fever treatment by malaria test result across all private outlets
a Primarily quinine injections, tablets, syrups as well as SP tablets and a few chloroquine tablet anti-malarials
b Primarily artemether injections
Malaria test positive
% (95% CI)
N = 266
Malaria test negative
% (95% CI)
N = 250
Not tested
% (95% CI)
N = 753
Any anti-malarial 83.0 (74.6–89.0) 14.3 (9.3–21.2) 50.8 (44.4–57.3)
Any ACT 60.0 (53.3–66.3) 10.2 (6.5–15.5) 42.7 (36.4–49.3)
QA ACT 48.5 (41.3–55.7) 6.6 (3.7–11.6) 33.9 (27.7–40.7)
Non-quality assured ACT 12.2 (8.1–18.1) 3.5 (1.3–9.4) 8.9 (5.6–13.7)
Non-artemisinin  therapya 14.4 (9.6–21.1) 3.6 (1.3–9.3) 8.4 (5.9–11.8)
Artemisinin  monotherapyb 14.9 (9.3–23.0) 0.5 (0.1–3.6) 1.1 (0.4–3.3)
Antibiotic 42.5 (34.1–51.3) 54.7 (45.7–63.4) 24.1 (18.9–30.1)
Antipyretic 78.7 (71.4–84.5) 61.2 (50.6–70.9) 64.9 (59.5–70.0)
Patient received a prescription for an anti-malarial, but did not 
receive an anti-malarial at the outlet (exiting without treat-
ment)
0.2 (0.1, 0.8) 3.3 (0.7, 14.4) 0.2 (<0.1, 1.8)
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This is concurrent with other research that most patients 
seek treatment from the private sector in Uganda [20–
23]. Most of the anti-malarials distributed by the private 
sector were ACT, though one in five anti-malarials dis-
tributed were SP, which was notably less expensive than 
ACT. While in many cases, private providers use available 
malaria commodities to test fever cases and treat accord-
ing to test results, gaps exist in appropriate case manage-
ment. Findings point to recommendations for improving 
coverage of appropriate malaria case management.
Role of the private sector in malaria case management
Most of the private sector anti-malarial distribution 
was through drug stores, comprising one third of the 
anti-malarial market share followed by private for-profit 
facilities and pharmacies. Outlets that have been found 
to play an important role in anti-malarial distribution 
in other countries such as general retailers and itinerant 
drug vendors do not provide anti-malarials in Uganda, 
as evidenced by multiple ACTwatch survey rounds [20, 
21]. For example, in 2013, 1241 general retailers were 
screened for anti-malarials and none were found to be 
stocking these medicines [21].
Given the importance of drug stores in malaria case 
management in Uganda, what is known about them? 
They are authorized to sell over-the-counter medicines 
and should be licensed by the National Drug Author-
ity. National regulations stipulate that they should be 
staffed by qualified health providers and administration 
of medicines should follow national policies. However, 
in practice it is possible that a substantial proportion of 
these outlets are not registered [3, 24]. For example, a 
census of private outlets in three rural eastern districts 
of Uganda estimated that up to 77.1% of private vendors 
may be unlicensed [25]. These unlicensed drug stores are 
described as operating illegally and manned by unquali-
fied staff selling a range of prescription and non-prescrip-
tion medicines [3]. The presence of these unlicensed drug 
stores may be particularly common given evidence that 
the implementation of laws and regulations governing 
medical practice can be challenging [26].
Strategies to license drugs stores may help to regulate 
these outlets and allow them to be included as part of the 
formal health care system. Such efforts may be an impor-
tant means to improve access to quality malaria case 
management services. Several strategies in other coun-
tries have demonstrated that unlicensed providers have 
been successfully integrated into the formal health sys-
tem through training, supervision, business incentives, 
and accreditation [27]. However, systematic evaluations 
of these activities have rarely been conducted [28]. While 
allowing unlicensed drug shops to participate in future 
programmes may expand the reach of case management 
services, these should be aligned in the context of Ugan-
da’s national policy and regulatory framework.
Private sector readiness for appropriate malaria case 
management
Overall, there was high availability of ACT in the pri-
vate sector (80.7%). The findings illustrate there was high 
readiness to administer ACT in the private sector, reflect-
ing increasing availability of ACT over time in Uganda, as 
evidenced by data from previous outlet surveys [20, 21, 
29]. For example, among drug shops surveyed, the per-
centage of outlets stocking an ACT medicine increased 
over time from 12.9% in 2009, to 63.5% in 2011 and to 
75.1% in 2013. These findings reflect private sector initia-
tives in Uganda, including the AMFm and CPM, where 
in 2015, 8.48 million ACT doses had been delivered to 
private sector First Line Buyers, albeit at reduced levels 
since a peak of 19.4 million treatment doses in 2013 (per-
sonal communication, Global Fund).
While many private sector outlets have QAACT avail-
able following on initiatives to improve private sec-
tor availability, only a quarter have both QAACT and 
malaria blood testing available. Access to diagnostic test-
ing has remained low in the private sector, though previ-
ous ACTwatch national surveys in Uganda have generally 
reported an increase over the past decade [20, 21, 29]. 
In particular, testing availability was moderate to high 
in pharmacies and private for-profit facilities, but par-
ticularly low among drug stores. The findings also reflect 
population-based studies which have found that less than 
15% of febrile children under five received a malaria diag-
nostic test from the private sector in Uganda [18].
Low private sector availability of malaria blood testing 
can be partly explained by the national regulatory frame-
work which has only permitted the use of RDT among 
licensed private drug stores in pilot settings. However, 
the results from a pilot findings in Uganda are promis-
ing and suggest that these outlets can safely and correctly 
test for malaria with appropriate training, supervision, 
and record keeping [30, 31]. For example, RDT-positive 
patients were 5.6% points more likely to buy ACT and 
31.4% points more likely to buy other anti-malarials than 
those not tested at all [32]. While this suggests that a 
policy in favor of parasitological testing in licensed drug 
stores may foster increased access and appropriate case 
management of suspected malaria cases, scaling this 
up at a national level is not without its challenges. The 
experience of introducing RDT in the private sector in 
Cambodia over the last 10  years has shown challenges 
with RDT supply, as well as determining effective incen-
tives for private providers and patients to use these tests 
and adhere to their results [33]. In addition, other stud-
ies have shown that RDT may result in an increase in 
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prescription rates for antibiotics when RDTs were intro-
duced, particularly in RDT negative cases [34, 35]. This 
suggests that the introduction of RDTs may also have 
inadvertent effects on the use of other medicines.
Private sector anti‑malarial distribution
More than half of the anti-malarials distributed in the 
private sector were ACT (66.1%), and in 2015 ACT with 
the green leaf logo comprised 43.6% of the market share. 
Non-artemisinin therapy comprised one-fifth of the 
market share, with SP most commonly sold/distributed. 
While there were few differences between outlet types, 
QAACT market share was highest among drug stores.
The 2015 findings speak to positive improvements in 
the private sector market share since the implementation 
of the AMFm program, even while deliveries of ACT with 
the green leaf logo have been declining since 2013 as fund-
ing of co-paid ACT dropped in 2014 and 2015. In 2010, 
market share for any ACT in Uganda’s private sector was 
estimated at 5.1% and this increased to 38.5% in 2011. The 
findings from the most recent survey, reported here, illus-
trate a further 27.6% point increase of ACT market share. 
With most of this increase attributed to ACT with the 
green leaf, this suggests that positive improvements can 
be associated with the CPM ACT subsidy programme.
Despite widespread distribution of ACT, non-arte-
misinin therapies continued to be widely available in 
the private sector and there was still some distribution 
of these medicines, notably quinine and SP. Findings 
from the fever case management study also indicate that 
artemether injections were being administered for con-
firmed, uncomplicated malaria cases, despite outlets hav-
ing ACT in stock. While SP should continue to account 
for a portion of anti-malarial market share because 
this product is recommended for intermittent preven-
tive treatment in pregnancy (IPTp) [3], the substantial 
SP market share is cause for concern, and suggests it is 
being administered for malaria case management, against 
national (and international) guidelines. This is also sup-
ported by other evidence that suggests many of the SP 
products have packaging and patient instructions indi-
cating its use for uncomplicated malaria for all ages [36].
One reason for the widespread availability and distribu-
tion of non-artemisinin therapy may be related to price. 
The findings from the outlet survey show that QAACT 
was three times more expensive than SP. QAACT was 
also more expensive than artemether injection fever 
case management study. These price barriers could have 
driven patient demand and the decision by the provider 
to administer a less expensive treatment option rather 
than QAACT. In 2010, one of the AMFm supportive 
interventions included a recommended retail price (RRP) 
for QAACT, which was $0.47 for an adult dose and $0.12 
for a child dose, however consumer awareness raising 
activities had not yet been implemented by 2015. The 
results from this study demonstrate that the median price 
for an adult and child treatment was three times higher 
than the RRP, at $1.62 and $0.39 respectively. ACT retail 
prices therefore may not be low enough to achieve opti-
mal uptake, pointing to the need for a further reduc-
tion in ACT retail price [6, 11]. Implementation of the 
planned BCC should be a useful strategy to increase 
awareness of the recommended retail price for QAACT, 
and promote demand for this treatment at an affordable 
price. Such activities could be coupled with a strengthen-
ing policies and regulations to curtail the availability and 
distribution of non-artemisinin therapies for malaria case 
management in the private sector [37].
Confirmatory testing in the private sector
The fever case management findings point to sub-opti-
mal private sector case management, illustrating that 
even in  situations where malaria diagnostic testing is 
available, patients are not routinely tested. The findings 
demonstrate that among all respondents interviewed, 
less than half (44%) received a confirmatory test and this 
was even lower among those visiting drug stores (29%), 
where most treatment is sought. These findings however 
are also consistent with other research that has shown 
irrational treatment decisions by health providers despite 
availability of diagnostic tests [38–40].
The findings from the fever case management study 
highlight some of the complexities of malaria diagnosis. 
For example, one in four of the respondents interviewed 
were seeking treatment on behalf of someone else who 
was not present and therefore could not be tested. The 
findings also illustrate how the patient may have already 
been managed at a different facility—almost one in four 
respondents had sought treatment elsewhere prior to 
attending the outlet where they were interviewed. Simi-
larly, a proportion at the consultation had already been 
given an anti-malarial at a different facility.
Several other barriers to administering malaria con-
firmatory testing in the private sector have been docu-
mented. This includes whether or not private providers 
will have an economic incentive to promote and sell 
RDTs to patients considering the revenue that is gener-
ated from anti-malarials [32, 41]. There may also be con-
cern over what to do when a result from a test is negative 
[33]. From the patient’s perspective, there may also be a 
financial disincentive to purchase both a test and a medi-
cine. This study found that the price of a malaria test was 
less than the price of treatment with an ACT for adults. 
However for children, there was no financial incen-
tive to test before treatment because ACT treatment 
was cheaper than RDT testing. Although there was an 
Page 12 of 15ACTwatch Group et al. Malar J  (2017) 16:219 
apparent financial incentive to test before treatment with 
an ACT for adults, the price of testing was still higher 
than other available non-artemisinin therapies includ-
ing the popular option, SP. Furthermore, patients seeking 
malaria treatment may see the price of an RDT test on 
top of the price they must pay for treatment as an unnec-
essary cost. In fact, data from a previous study in Uganda 
illustrated that drug shop customers’ willingness-to-pay 
threshold for RDTs was considerably lower than the 
actual RDT price, with many preferring to spend their 
money on medicines rather than testing [42]. Thus, pro-
vider motivation and additional cost to patients for test-
ing remain important challenges to scaling-up diagnostic 
testing within the private sector.
Several strategies may be useful to overcome these 
barriers. One important strategy will be to build con-
sumer demand for testing. The findings from the fever 
case management study show that testing was available 
in private sector outlets, yet fewer than half of patients 
received a confirmatory test. Social and behavior change 
communication that targets patients and provides them 
with information and education on the importance of 
confirmatory testing, will be an important means to 
increase demand for testing. Demand side strategies 
could also be supported with several supply side inter-
ventions to ensure RDTs are affordable and accessible to 
patients. This may include bundling RDTs and ACT as a 
single commodity rather than two separate commodities 
[42], such that if the RDT was positive the patient could 
then be offered a free or highly subsided ACT. A voucher 
system for RDTs and ACT may be another fruitful avenue 
to consider, where a full refund of the RDT is offered for 
positive patients on the condition that they purchase an 
ACT [14]. Such private sector supply side strategies could 
be complemented with aforementioned patient-targeted 
BCC that promotes RDTs as a necessary and affordable 
commodity [3]. Of promise is that several strategies have 
demonstrated successful introduction of RDTs in Ugan-
da’s private sector [12, 13, 43]. Lessons from these stud-
ies can pave the way for future scale-up of confirmatory 
testing and can consider these several options to promote 
diagnostic testing among all patients.
Treatment according to test results in the private sector
The findings from the fever case management study show 
that among private sector outlets that had ACT and diag-
nostic services available, over 80% of patients who tested 
positive for malaria received an anti-malarial. While 
these results are promising, there is still a gap given 
that one in five patients did not receive an anti-malarial, 
despite a confirmed positive blood test. It is not clear 
from the results of this study why these confirmed posi-
tive cases did not receive appropriate treatment as these 
outlets were all stocking ACTs. This could be related to 
price or patient demand for certain treatments, and/
or that patients may have had other options for obtain-
ing treatment elsewhere or at home. While anti-malarial 
treatment was high among confirmed cases, treatment 
with an ACT was lower at 60%, highlighting the problem 
of availability and administration of non-ACTs for treat-
ment of uncomplicated malaria.
The results also illustrate that within the private sec-
tor, that patients who are not tested commonly receive 
treatment with an antipyretic. Treating fever with an 
antipyretic is appropriate, but patients presenting with 
fever and are not being tested are a missed opportunity 
to catch what may be malaria infection and treat it appro-
priately. Furthermore, half of people not tested were 
treated with an anti-malarial and confirmatory testing 
prior to treatment could reduce what may be irrational 
anti-malarial use.
Administration of an antibiotic was quite high among 
those with a positive test result (42.5%) and many patients 
also purchased several medicines, including antipyretics. 
These findings are consistent with other studies imple-
mented in Uganda’s private sector, which have found 
widespread administration of antibiotics and antipyretics 
among RDT positive patients [13].
Several studies have suggested that while there is a 
reduction in anti-malarial treatment after RDT introduc-
tion [5–8], anti-malarials are administered despite nega-
tive test results. Findings from this study are promising 
given that anti-malarial and specifically ACT prescrip-
tion among malaria negative patients was low, and lower 
than what has been observed in other studies [9–12]. 
There may be several reasons as to why anti-malarials are 
still administered despite a negative test result, including 
concerns of patient safety [44], a mistrust of negative test 
results [45], or uncertainty as to what to do when faced 
with a negative result [46].
One way to encourage providers to administer RDT 
and adhere to test results may include increasing prod-
uct awareness, both among patients to drive demand, but 
also for providers to stock and sell RDT. This may require 
intense BCC activities, as well as provider training. The 
complexity of messaging is also noted as a key challenge, 
given there is more than one message and one objective 
[33]. It has been suggested that messaging should pro-
mote the need to be tested prior to treatment, to take a 
recommended first-line treatment, and if test results are 
negative to urge the patient not to take an anti-malarial. 
A key challenge remaining for providers is what to do 
if the patient tests negative. Simple algorithms may be 
helpful, but additional provider training and support, as 
well as a network of referral systems will be necessary to 
address these obstacles.
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Limitations
The sample for the fever case management study was 
dependent upon the findings from the concurrently 
implemented ACTwatch outlet survey, which has previ-
ously documented limitations [19, 47]. In the fever case 
management study, the outlets were identified through 
the outlet survey census, and only those outlets with 
ACT and diagnostics were included. Due to the small 
time lag between the outlet survey and the fever case 
management study, some previously eligible facilities 
may have lost eligibility after having stock-outs of either 
ACT or RDTs. Furthermore, there are notable challenges 
with observational studies, particularly where multiple 
data-collecting observers are used as was in the case 
of this study. It is possible that the observers may have 
differed in the consistent identification, discrimination 
and recording of data. It is also likely that social desir-
ability biases may have played a role in affecting pro-
vider behavior. The presence of fieldworkers observing 
provider practices may have led to some change in their 
behaviour.
Conclusion
The private sector is a common source of anti-malarial 
treatment for people in Uganda. While many private 
sector outlets have QAACT available following on from 
initiatives to improve private sector availability, only one-
quarter have both QAACT and testing available. Results 
show that in many instances, private providers who 
stock ACT and malaria blood testing often use available 
commodities to appropriately manage patients. How-
ever, gaps persist in ensuring all fever patients receive a 
confirmatory test and QAACT. There is need to further 
promote confirmatory testing and ACT among patients 
and private sector providers, as well as discourage the 
use of non-artemisinin therapies and inappropriate use 
of injectable artemisinin monotherapies for cases of 
uncomplicated malaria.
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